BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

KEYTRUDA: trial readouts and FDA decisions

1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 1 readout(s) in the last 180 days and 6 FDA event(s) in the last 12 months. Sponsors: MERCK SHARP DOHME, Innovent Biologics (Suzhou) Co. Ltd., Binhui Biopharmaceutical Co., Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT07122687 IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell LungResectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancerrecruiting170

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-10-16FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2026-10-16: KEYTRUDA (BLA125514 SUPPL191)
2026-07-10FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2026-07-10: KEYTRUDA (BLA125514 SUPPL194)
2026-06-24FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2026-06-24: KEYTRUDA (BLA125514 SUPPL187)
2026-06-12FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2026-06-12: KEYTRUDA (BLA125514 SUPPL192)
2026-02-10FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2026-02-10: KEYTRUDA (BLA125514 SUPPL186)
2025-11-21FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2025-11-21: KEYTRUDA (BLA125514 SUPPL188)

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-06-02P1/P2Binhui Biopharmaceutical Co., Ltd.NCT04386967 OH2 Injection in Solid TumorsSolid Tumor; Melanomacompleted44

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.